130 related articles for article (PubMed ID: 24899604)
1. Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
Li YC; Wang HH; Liao AJ; Fu BB; Zhang R; Li J; Yang Y; Liu ZG; Yang W
Eur Rev Med Pharmacol Sci; 2014; 18(10):1465-72. PubMed ID: 24899604
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
3. [Effect of bortezomib on MAPK signaling pathway of K562/DNR cells].
Liao AJ; Fu BB; Wang HH; Li YC; Yao K; Zhang R; Yang W; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1460-3. PubMed ID: 21176351
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Zheng B; Zhou R; Gong Y; Yang X; Shan Q
Int J Lab Hematol; 2012 Jun; 34(3):237-47. PubMed ID: 22145750
[TBL] [Abstract][Full Text] [Related]
5. [Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].
Fu BB; Fan Y; Hao LC; Liao AJ; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):671-5. PubMed ID: 21729547
[TBL] [Abstract][Full Text] [Related]
6. Reversion of Multidrug-Resistance by Proteasome Inhibitor Bortezomib in K562/DNR Cell Line.
Wang HH; Li YC; Liao AJ; Fu BB; Yang W; Liu ZG; Wang XB
Chin J Cancer Res; 2011 Mar; 23(1):69-73. PubMed ID: 23467537
[TBL] [Abstract][Full Text] [Related]
7. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Lü S; Chen Z; Yang J; Chen L; Zhou H; Xu X; Li J; Han F; Wang J
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e123-31. PubMed ID: 19254348
[TBL] [Abstract][Full Text] [Related]
8. [Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].
Shang J; Chen ZZ; Wu WB; Wei TN; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):911-6. PubMed ID: 23363746
[TBL] [Abstract][Full Text] [Related]
9. [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Zhou RQ; Gong YP; Zheng BH; Yang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):789-92. PubMed ID: 21302442
[TBL] [Abstract][Full Text] [Related]
10. [Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].
Jiang HN; Liu ZG; Hu R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1342-1349. PubMed ID: 29070105
[TBL] [Abstract][Full Text] [Related]
11. [Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
Lu SF; Lu H; Shen WY; Zhang JF; Liu P; Wang YR; Wang LX; Yang H; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1006-9. PubMed ID: 18928584
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
13. [Effect of PDMP, a glucosylceramide synthase inhibitor, on reversion of daunorubicin resistance in human leukemia cell line K562/A02].
Yin L; Chen BA; Cheng J; Ding JH; Gao C; Sun YY; Wang J; Zhao G; Gao F; Song HH; Bao W; Wu WW; Wang F; Liang YQ; Xia GH; Wang XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):79-84. PubMed ID: 20137123
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
15. [Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism].
Wu HY; Wang SM; Huang JQ; Hao LM; Li XM; Wei LY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1361-4. PubMed ID: 23257433
[TBL] [Abstract][Full Text] [Related]
16. [Effect of proteasome inhibitor bortezomib on proliferation, apoptosis and SHIP gene expression in K562 cells].
Jia ZQ; Wei YT; Li AM; Cheng ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):916-9. PubMed ID: 23998585
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
18. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
